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 ABSTRACT
Coronavirus disease 2019 (COVID-19), now a global pan-
demic, has infected millions of people and caused hundreds 
of thousands of deaths. Neurological presentation of the 
novel coronavirus includes headaches, seizures, myalgias, 
hyposmia, ageusia, etc. Guillain-Barre Syndrome (GBS) 
and its variant, Miller Fisher Syndrome, have been re-
ported in COVID-19 patients presenting with lower limb 
weakness, paresthesia, facial diplegia, and ataxia. Most re-
cently, large vessel occlusion strokes were seen in infected 
younger patients without vascular risk factors. We present 
a novel case of rhabdomyolysis associated with COVID-19 
infection in a patient on atorvastatin, in whom we detected 
positive anti-transcriptional intermediary factor 1 gamma 
antibodies (anti-TIF1-y Ab). Bilateral upper and lower ex-
tremity weakness improved with aggressive fluid adminis-
tration and intravenous immunoglobulin (IVIg) at 0.4mg/
kg for a total of 5 days. Interrupting a strong cytokine re-
sponse with IVIg early on during the disease may have led 
to rapid improvement. 
Keywords: COVID-19, SARS-CoV-2, rhabdomyolysis, my-
ositis, inflammatory myopathy, anti-TIF1-y antibody.
Background
Coronavirus disease 2019 (COVID-19), the disease caused 
by the novel coronavirus severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), has come a long way since 
it was first discovered in several patients in Wuhan, China 
on December 2019.1 Now a global pandemic, it has infected 
millions of people and caused hundreds of thousands of 
deaths. Over a short span of time, the virus has revealed its 
nature, presenting with more than just severe respiratory 
symptoms. Neurological symptoms such as headaches, 
seizures, and loss of consciousness, hyposmia, myalgias, 
and ageusia have been reported to be associated with this 
novel virus.2-6 In Italy, one of the most severely hit by the 
pandemic, five patients with COVID-19 presented with 
lower limb weakness and paresthesia, with one patient 
presenting with facial diplegia and ataxia, consistent with 
Guillain-Barre Syndrome (GBS)7. Miller Fisher syndrome, 
a variant of GBS, was described on a patient in Spain.8 
Most recently, large vessel occlusion strokes have been 
seen in younger patients with COVID-19 who did not have 
significant risk factors9. Indeed, this novel virus has caused 
a myriad of neurological symptoms, and neurologists are 
presented with the challenge of managing these patients 
without specific guidelines and with limited current data. 
We present a novel case of rhabdomyolysis associated with 
COVID-19 infection in a patient on atorvastatin, no rash 
but a positive anti-TIF1-y antibody titer found on myositis 
panel.
Case
A 69-year-old female was admitted to our hospital with 
a one-week history of progressive, severe arm and leg 
weakness and unsteadiness. She endorsed difficulty lifting 
her arms above her shoulders, with associated muscle pain. 
She had a recent normal mammogram. She also reported 
difficulty swallowing with both liquids and solid foods. She 
had a low grade fever at 99.1 F, tachycardia, as well as mild 
cough, which prompted a virus screen. Influenza A and B 
rapid testing were negative, but her PCR for SARS-CoV-2 
came back positive. A computed tomography angiogram 
(CTA) scan of the chest was done, which revealed linear 
opacities involving the right upper lobe and both lower lobes, 
and several areas of minimal non rounded ground glass 
opacities involving the dependent aspects of both lobes. 
There was no evidence of pulmonary embolus. There were 
no physical or laboratory findings indicative of dehydration. 
Her inflammatory markers were elevated: D-dimer of 4,281 
ng/mL (215-500 ng/mL), and C-reactive protein (CRP) 
of 1.6 mg/dL (0-0.3 mg/dL).   Her creatinine kinase (CK) 
was elevated at 4,499 U/L (26-192 U/L), along with serum 
myoglobin at 2,132 ng/mL (13-17 ng/mL), and aldolase of 
14.1 (1.5-8.1 U/L). She did not have any myoglobinuria, and 
her urine was negative for red blood cells (RBCs).
Neurology was consulted for her weakness and dyspha-
gia. She was alert and oriented on initial examination, with-
out dysarthria or aphasia noted, but her speech was hypo-
phonic. Although there was no facial asymmetry nor ptosis at 
rest, she had some weakness of her facial musculature, with 
some air escaping when puffing cheeks. She had no trouble 
with eyelid closure. Bilateral shoulder flexors and the rest of 
her upper extremity proximal muscles were 3-/5 on manual 
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muscle testing, and 4+/5 distally for both wrists and fin-
gers. Her hip flexors were bilaterally 3/5, and 4+ /5 on knee 
flexion, extension, as well as ankle dorsiflexion and plan-
tarflexion bilaterally. She endorsed muscle pain on move-
ment which may have somewhat influenced her effort dur-
ing testing. Sensory examination was normal to light touch 
and temperature. Reflexes were 2 both for upper limbs, 1 for 
both knees, and were absent at the ankles bilaterally. She 
was able to walk with slow gait and with some assistance. 
MRI of her brain showed an incidental small meningioma 
with very minimal mass effect on the inferior frontal falx. 
Acetylcholine receptor antibody (Ab) and muscle specific 
antibody (MuSK) were both negative. Myositis panel was 
normal, except for anti-TIF1-y (p155/140) Ab (Table 1). She 
did not present with any rashes, nor does she have a history 
of cancer. As the patient was taking 40mg of atorvastatin for 
several years for dyslipidemia, 3-hydroxy-3-methylgutaryl 
coenzyme A reductase (HMGCR) Ab was obtained to evalu-
ate for statin-associated autoimmune necrotizing myopathy 
(SANAM), which was negative. Atorvastatin was stopped on 
admission. Rheumatologic labs were also obtained and were 
negative, including ANA, Rheumatoid factor, ANCA vascu-
litis panel, RNP ab and anti-Smith ab.
Throughout the admission, the patient’s respiratory 
status remained stable, her oxygen saturation levels well 
over 90% on room air. No antibiotics were given, and she 
was placed on IV fluids for her rhabdomyolysis. However, 
on Day 4 of admission, her CK levels continued to rise, 
reaching its peak of 5,456 (26-192) U/L, despite aggressive 
hydration and supportive care. She was then started em-
pirically on immunoglobulin (IVIg) at 0.4mg/kg for 5 days. 
The day after the first dose, her CK started to trend down. 
She denied any side effects with the IVIg treatment. After 
completing her immunotherapy on Day 8 of admission, the 
patient noted subjective improvement of her lower extrem-
ity weakness. On Day 12 of admission, her hip flexors were 
3+ to 4/5 bilaterally approximately, and she had increased 
range of motion on shoulder flexion and abduction. Func-
tionally, her walking was better, and she had increased use 
of her arms without significant pain. Her CK on Day 12 was 
2,617 (26-192) U/L. She was discharged on Day 21 of ad-
mission, and has a follow up visit in the neurology clinic.
Discussion
Our patient presented with the typical viral pro-
drome of myalgia and generalized muscle weakness while 
on chronic stable statin dosage. Rhabdomyolysis is not as 
widely reported with COVID-19 as myalgias. In fact, my-
algia is a very common symptom in COVID-19, with up 
to 44% of confirmed cases in an institutional review of by 
Huang, et al.5 However, Guan et al reported only 2 patients 
with rhabdomyolysis (muscle pain or muscle weakness, and 
CK > 10 times the upper limit of normal) out of 1099 with 
confirmed COVID-19 from 552 different hospitals in main-
land China.4 Beydon, et al presented another case in France, 
where the patient presented with myalgia and initial CK of 
25,384 IU/L. MRI of the lower extremity showed muscle 
edema and their patient was treated with IV fluids.10 
Lin, et al recently postulated that B lymphocyte reduc-
tion might occur during the early phase of severe COVID-19 
infection, together with T lymphocyte reduction, as well as 
an increase in inflammatory cytokines and D-dimer.11 This 
Table 1: Myositis Panel
Antibody Result
MI-2 Negative
PL-7 (threonyl-tRNA synthetase) Negative
PL-12 (alanyl-tRNA synthetase) Negative
P155/140 (TIF1-gamma) Positive
EJ (glycyl-tRNA synthetase Negative
Ku Negative
SRP (Signal Recognition Particle) Negative
OJ (isoleucyl-tRNA synthetase) Negative
SAE (SUMO activating enzyme) Negative
NXP-2 (Nuclear Matrix Protein 2) Negative
MDA5 (CADM-140) Negative
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immune response is the basis for their recommendation to 
initiate high dose IVIg at 0.3-0.5g/kg per day for 5 days, to 
potentially interrupt the storm of inflammatory factors and 
enhance immune function.11 While our patient in retrospect 
had milder COVID-19 disease, she was initially treated 
with IV fluids but continued to have an increase in CK lev-
els. After receiving IVIg, her CK declined and her myalgia 
and weakness improved. While D-dimer was highly elevat-
ed, our patient was anticoagulated. She did not experience 
any thrombotic or other adverse event as a result of IVIg. 
The administration of IVIg in COVID-19 patients present-
ing with other neurological conditions has been shown to be 
safe and effective as well with concomitant anticoagulation. 
The five COVID-19 patients earlier mentioned with con-
firmed GBS from Italy all received IVIg. Two had a second 
course of IVIg, and one had subsequent plasma exchange 
(PLEX). 7 A Miller Fisher case with COVID-19 infection 
described in Spain recovered completely following IVIg 
treatment.8
We initially did not consider an autoimmune muscle 
injury mechanism in this case given negative serologies 
(ANA, RF, etc.) and swift response to IVIg. An interesting 
later finding in this case, however, was the presence of anti-
TIF1-y antibody on myositis panel. Anti-TIF1-y ab is one of 
the autoantibodies associated with inflammatory myopa-
thies, particularly in dermatomyositis. Adult dermatomyo-
sitis patients with anti-TIF1-y have a higher frequency of 
cancer, up to 70%, as compared to those who are antibody 
negative.14 Our patient did not present with the typical skin 
lesions associated with dermatomyositis. She also did not 
have a history of cancer, no evidence of cancer on chest CT 
or prior mammogram. Masiak et al, in a single center study 
of 80 patients with a positive autoimmune inflammatory 
myopathy profile, 11 were positive for anti-TIFI-y antibod-
ies, 6 were diagnosed with dermatomyositis, and 2 had a 
neoplasm. Interestingly, one patient in that study present-
ed with rhabdomyolysis with severe muscular weakness.12 
Therefore, we suspect that the immune response may have 
contributed to our patient’s rhabdomyolysis. 
We hypothesize that the immune activation in the set-
ting of milder COVID-19 infection may have resulted in this 
positive antibody titer. This complex infection triggers the 
recruitment of macrophages and monocytes, the release of 
cytokines and adaptive T and B cells to target cells.15 Most 
cases of COVID-19 are mild, as was the case in our patient, 
and this inflammatory process is capable of resolving this 
infection. This is thought to be the result of a well-function-
ing immune system. We think that our patient who had a 
milder infection was able to generate an adequate immune 
response to COVID-19, part of which was the de novo pro-
duction of anti-TIF1-y cross-reacting antibodies. Alterna-
tively, that COVID-19 uncovered a predisposition to myo-
sitis in the setting of a mild infection cannot be excluded. 
Our case report has several limitations including lack 
of outpatient follow up. In addition, electromyography and 
nerve conduction study (EMG/NCS) would have been a 
useful diagnostic tool to assist us in further characteriza-
tion of the patient’s muscle weakness. In addition, a muscle 
biopsy would also have been beneficial in describing the his-
topathological features. However, the limitations posed by 
isolation precautions, as well as strained health resources 
and organizational barriers due to the pandemic hindered 
us from performing any of these procedures. 
In conclusion, rhabdomyolysis, as reported herein, is 
rare in the setting of acute COVID-19 infection. We cannot 
exclude that statin therapy may have triggered rhabdomy-
olysis. However, the elevation of anti-TIF1-y antibody ti-
ter suggests that COVID-19 infection has the potential to 
uncover or even trigger an autoimmune response targeting 
muscle. An international database is critically important to 
better capture rare neuromuscular complications of CO-
VID-19 and to better characterize the acute and long-term 
neuromuscular sequelae of this pandemic.
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